Antivascular activity of lapatinib and bevacizumabtermterm in primary microcluster cultures of breast cancer and other human neoplasms

Sub-category: New Systemic Agents - New drugs and targets (includes anti-angiogenics) - Other

Category: Treatment

Meeting: 2008 Breast Cancer Symposium

Abstract No: 166

Author(s): L. Weisenthal, D. J. Lee, N. Patel

Abstract:

Background:

The following tyrosine kinase inhibitors (TKI) have been shown to have antivascular (AV) activity: sunitinibterm (Su), sorafenibterm (So), gefitinib (G), erlotinib (E), and imatinib (I). To date, AV activity has not been reported for lapatinib (LAP).